Toll-like receptor 4 in COVID-19: friend or foe?

被引：37
|
作者：
Mukherjee, Suprabhat [1 ]
机构：
[1] Kazi Nazrul Univ, Dept Anim Sci, Integrat Biochem & Immunol Lab, Asansol 713340, W Bengal, India
来源：
FUTURE VIROLOGY | 2022年 / 17卷 / 07期
关键词：
COVID-19; cytokine storm; immunotherapy; SARS-CoV-2; TLR4; TLR4;
D O I：
10.2217/fvl-2021-0249
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
Tweetable abstract Toll-like receptor 4, an innate immune sensor, is one of the key 'fate-deciding' regulators of immunity as well as COVID-19 immunopathogenesis. Suitable targeting of Toll-like receptor 4 appears to be an effective strategy to counteract the pandemic.
引用
收藏
页码：415 / 417
页数：3
相关论文
共 50 条
  • [1] Toll-like receptor (TLRs) agonists and antagonists for COVID-19 treatments
    Liu, Zhi-Mei
    Yang, Ming-Hui
    Yu, Kun
    Lian, Zheng-Xing
    Deng, Shou-Long
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [2] Is Toll-like receptor 4 involved in the severity of COVID-19 pathology in patients with cardiometabolic comorbidities?
    Brandao, Simone Cristina Soares
    Ramos, Julia de Oliveira Xavier
    Dompieri, Luca Terracini
    Godoi, Emmanuelle Tenorio Albuquerque Madruga
    Figueiredo, Jose Luiz
    Sarinho, Emanuel Savio Cavalcanti
    Chelvanambi, Sarvesh
    Aikawa, Masanori
    CYTOKINE & GROWTH FACTOR REVIEWS, 2021, 58 : 102 - 110
  • [3] The immune system and COVID-19: Friend or foe?
    Yazdanpanah, Fereshteh
    Hamblin, Michael R.
    Rezaei, Nima
    LIFE SCIENCES, 2020, 256
  • [4] Serum soluble toll-like receptor 4 and risk for clinical severity in COVID-19 patients
    Maha E. Houssen
    Marwa O. Elmaria
    Dina Badr
    Rasha El-Mahdy
    Mayada A. Ghannam
    Shaimaa El-Ashwah
    May Denewer
    Metwaly Ibrahim Mortada
    Pneumonia, 16
  • [5] Serum soluble toll-like receptor 4 and risk for clinical severity in COVID-19 patients
    Houssen, Maha E.
    Elmaria, Marwa O.
    Badr, Dina
    El-Mahdy, Rasha
    Ghannam, Mayada A.
    El-Ashwah, Shaimaa
    Denewer, May
    Mortada, Metwaly Ibrahim
    PNEUMONIA, 2024, 16 (01)
  • [6] NSAIDs in COVID-19, friend or foe?
    Mahrous, Reham
    Abdelnasser, Amr
    Fouda, Raghda
    Morsy, Mohamed Abd Al Moniem
    Mandour, Omnia
    ANAESTHESIA PAIN & INTENSIVE CARE, 2023, 27 (01) : 119 - 122
  • [7] COVID-19 and hypertension: Is there a role for dsRNA and activation of Toll-like receptor 3?
    Dela Justina, Vanessa
    Giachini, Fernanda R.
    Priviero, Fernanda
    Webb, R. Clinton
    VASCULAR PHARMACOLOGY, 2021, 140
  • [8] Role of Toll-like receptors in the pathogenesis of COVID-19
    Khanmohammadi, Shaghayegh
    Rezaei, Nima
    JOURNAL OF MEDICAL VIROLOGY, 2021, 93 (05) : 2735 - 2739
  • [9] Oxygen: Friend or foe in the COVID-19 battle
    Chudasama, Kishan
    Sangey, Esmail
    CLINICAL CASE REPORTS, 2021, 9 (12):
  • [10] The investigation of host genetic variants of toll-like receptor 7 and 8 in COVID-19
    Bagci, Gokhan
    Gundogdu, Oguz
    Pektas, Ayse Nur
    Bagci, Binnur
    Avci, Onur
    Gursoy, Sinan
    Kaygusuz, Kenan
    Elaldi, Nazif
    NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 2023, 42 (08) : 586 - 602
12345